Literature DB >> 22435728

Suicide attempt with an overdose of imatinib.

Osamu Iketani, Tomoki Ueda, Yasuko Yamayoshi, Masaya Yamaguchi, Shunichi Kawamura, Shinichiro Okamoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22435728      PMCID： PMC3495154          DOI： 10.1111/j.1365-2125.2012.04275.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  10 in total

Review 1.  Histogenesis, structure and relationships of interstitial cells of Cajal (ICC): from morphology to functional interpretation.

Authors:  M S Faussone-Pellegrini
Journal:  Eur J Morphol       Date:  1992

2.  Overdose with 6400 mg of imatinib: is it safe?

Authors:  R Bhargav; M Mahapatra; P Mishra; R Kumar
Journal:  Ann Oncol       Date:  2007-10       Impact factor: 32.976

3.  Effects of imatinib mesylate in interstitial cells of Cajal from murine small intestine.

Authors:  Byung Joo Kim; Han Chae; Young Kyu Kwon; Seok Choi; Jae Yeol Jun; Ju-Hong Jeon; Insuk So; Seon Jeong Kim
Journal:  Biol Pharm Bull       Date:  2010       Impact factor: 2.233

4.  Imatinib inhibits spontaneous rhythmic contractions of human uterus and intestine.

Authors:  Laurentzio M Popescu; Cristina Vidulescu; Antoanela Curici; Laura Caravia; Anca A Simionescu; Sanda M Ciontea; Sorin Simion
Journal:  Eur J Pharmacol       Date:  2006-07-05       Impact factor: 4.432

Review 5.  Clinical pharmacokinetics of imatinib.

Authors:  Bin Peng; Peter Lloyd; Horst Schran
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

6.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

Authors:  Hagop Kantarjian; Charles Sawyers; Andreas Hochhaus; Francois Guilhot; Charles Schiffer; Carlo Gambacorti-Passerini; Dietger Niederwieser; Debra Resta; Renaud Capdeville; Ulrike Zoellner; Moshe Talpaz; Brian Druker; John Goldman; Stephen G O'Brien; Nigel Russell; Thomas Fischer; Oliver Ottmann; Pascale Cony-Makhoul; Thierry Facon; Richard Stone; Carole Miller; Martin Tallman; Randy Brown; Michael Schuster; Thomas Loughran; Alois Gratwohl; Franco Mandelli; Giuseppe Saglio; Mario Lazzarino; Domenico Russo; Michele Baccarani; Enrica Morra
Journal:  N Engl J Med       Date:  2002-02-28       Impact factor: 91.245

7.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

8.  Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.

Authors:  Bin Peng; Michael Hayes; Debra Resta; Amy Racine-Poon; Brian J Druker; Moshe Talpaz; Charles L Sawyers; Marianne Rosamilia; John Ford; Peter Lloyd; Renaud Capdeville
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

9.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

10.  Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.

Authors:  Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Francis Giles; Guillermo Garcia-Manero; Stefan Faderl; Deborah Thomas; Jianqin Shan; Mary Beth Rios; Jorge Cortes
Journal:  Blood       Date:  2002-09-12       Impact factor: 22.113
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.